

Serial No.: 09/613,038

REMARKS

Responsive to a suggestion by Examiner Nguyen in a telephone interview on December 23, 2002, Applicants are amending the pending claims herein to (1) update the dependency of claims 6-8, 13 and 16 in view of the previous cancellation of claim 2; (2) change "antagonist" to "antibody" in claims 11-12 in view of the previous amendment of claim 1 to refer to an "antibody" therein; and (3) cancel claim 31, without prejudice or disclaimer, due to the previous cancellation of claim 30. In that the amendments do not introduce new matter, entry thereof is respectfully requested.

Respectfully submitted,
GENENTECH, INC.

Date: December 30, 2002

By: Wendy Lee
Wendy Lee
Reg. No. 40,378
Telephone: (650) 225-1994



09157

PATENT TRADEMARK OFFICE

Serial No.: 09/613,038

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend the following claims:

6. (Amended) The method of claim [2] 1 wherein the antibody is not conjugated with a cytotoxic agent.

7. (Amended) The method of claim [2] 1 wherein the antibody comprises rituximab.

8. (Amended) The method of claim [2] 1 wherein the antibody is conjugated with a cytotoxic agent.

11. (Amended) The method of claim 1 comprising administering the [antagonist] antibody intravenously.

12. (Amended) The method of claim 1 comprising administering the [antagonist] antibody subcutaneously.

13. (Amended) The method of claim [2] 1 comprising administering a dose of substantially less than 375 mg/m² of the antibody to the mammal.

16. (Amended) The method of claim [2] 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m² dose of the antibody in the subsequent dose exceeds the mg/m² dose of the antibody in the initial dose.

Please cancel claim 31, without prejudice or disclaimer.